SA
ONC logo
BeOne Medicines AG(ONC)
Last print unknown agoAbout this dataData status
$395.26▼-4.44 (-1.11%)Stale · unknown old

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 31.4 · very high volatility

Overview →

BeOne Medicines AG (ONC)

R&D to Revenue

38.81%

Fiscal year · Period ending:

ONC logo

ONC R&D to Revenue

Latest reported38.81%
ONC FY R&D/Revenue (120.77% → 38.81%)
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

ONC r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

BeOne Medicines AG R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
38.806%
51.2643%
72.3365%
115.8615%
124.0551%
419.225%
216.5605%
342.5512%
112.8493%
9,161.9626%
660.7305%
167.7177%
120.7661%

Frequently asked questions: ONC r&d to revenue

What is BeOne Medicines AG (ONC)'s current r&d to revenue?

BeOne Medicines AG (ONC)'s latest reported r&d to revenue (Fiscal year) is 38.81% as of Dec 31, 2025. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for ONC?

Stock Alarm Pro provides 13 dated annual fiscal periods observations for BeOne Medicines AG (ONC)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare ONC's r&d to revenue to peers or set an alert?

You can open ONC's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on ONC delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.